Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CNTNAP1 antisense RNA 1 (CNTNAP1-AS1) appears to refer to a putative antisense noncoding RNA transcript at the CNTNAP1 gene locus. No research has characterized it as a therapeutically actionable target, receptor, enzyme, or other classical drug target. The current literature and databases focus exclusively on the protein-coding gene CNTNAP1 and its protein product CASPR, which plays critical roles in neuronal development, axoglial interactions, and myelination[1][2][3]. CNTNAP1-AS1 has not been identified as a validated gene, protein, or target in peer-reviewed literature, is not associated with common aliases, has no described biological functions, disease roles, interacting drugs, or mechanisms of action, and is not used as a biomarker or associated with safety concerns. This suggests the entry is incorrect or lacks sufficient information to be considered a molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CNTNAP1 antisense RNA 1 (CNTNAP1-AS1).